MX2019001814A - Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart. - Google Patents
Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.Info
- Publication number
- MX2019001814A MX2019001814A MX2019001814A MX2019001814A MX2019001814A MX 2019001814 A MX2019001814 A MX 2019001814A MX 2019001814 A MX2019001814 A MX 2019001814A MX 2019001814 A MX2019001814 A MX 2019001814A MX 2019001814 A MX2019001814 A MX 2019001814A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- hiv infection
- haart
- antibodies
- sustained virologic
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title abstract 3
- 208000037357 HIV infectious disease Diseases 0.000 title abstract 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title abstract 3
- 230000002459 sustained effect Effects 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374752P | 2016-08-13 | 2016-08-13 | |
| PCT/US2017/046668 WO2018035001A1 (en) | 2016-08-13 | 2017-08-13 | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001814A true MX2019001814A (es) | 2019-07-08 |
Family
ID=61197201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001814A MX2019001814A (es) | 2016-08-13 | 2017-08-13 | Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11292839B2 (enExample) |
| EP (1) | EP3497133A4 (enExample) |
| JP (1) | JP2019534891A (enExample) |
| KR (1) | KR20190071677A (enExample) |
| CN (1) | CN109996815A (enExample) |
| AU (1) | AU2017312887A1 (enExample) |
| BR (1) | BR112019002734A2 (enExample) |
| CA (1) | CA3033728A1 (enExample) |
| MX (1) | MX2019001814A (enExample) |
| RU (1) | RU2019106804A (enExample) |
| SG (2) | SG10202100268RA (enExample) |
| TW (1) | TW201808998A (enExample) |
| WO (1) | WO2018035001A1 (enExample) |
| ZA (1) | ZA201901374B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019106804A (ru) * | 2016-08-13 | 2020-09-21 | Юнайтед Байофарма, Инк. | Лечение и устойчивая вирусологическая ремиссия при вич-инфекции у haart-стабилизированных пациентов с помощью антител против cd4 |
| US12384830B2 (en) | 2017-06-02 | 2025-08-12 | Regents Of The University Of Minnesota | Compositions and methods for improving immunotherapy |
| CN113825766A (zh) * | 2019-05-16 | 2021-12-21 | 南京传奇生物科技有限公司 | 包含cd4结合部分的免疫细胞受体 |
| TW202321457A (zh) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | 靶向ｃｄ４之病毒載體之用途 |
| US20250059560A1 (en) | 2021-12-16 | 2025-02-20 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250144235A1 (en) | 2022-02-02 | 2025-05-08 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| EP4590688A1 (en) | 2022-09-21 | 2025-07-30 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4381295A (en) | 1979-04-26 | 1983-04-26 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human helper T cells and methods of preparing same |
| DE3828582A1 (de) | 1988-08-23 | 1990-03-01 | Max Planck Gesellschaft | Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren |
| EP0365209A3 (en) | 1988-10-17 | 1990-07-25 | Becton, Dickinson and Company | Anti-leu 3a amino acid sequence |
| JPH0725794B2 (ja) | 1990-03-23 | 1995-03-22 | 呉羽化学工業株式会社 | 新規なペプチド |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2101834T3 (es) | 1990-11-27 | 1997-07-16 | Biogen Inc | Anticuerpos anti-cd4 que bloquean sincitios inducidos por vih. |
| JPH06125783A (ja) | 1991-12-28 | 1994-05-10 | Chemo Sero Therapeut Res Inst | 組換え抗ｈｉｖ抗体およびその調製方法 |
| WO1995024483A1 (en) | 1994-03-08 | 1995-09-14 | Scotgen Biopharmaceuticals, Inc. | Recombinant humanized anti-fb5 antibodies |
| US5961976A (en) | 1996-06-03 | 1999-10-05 | United Biomedical, Inc. | Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV |
| JP3231262B2 (ja) | 1996-06-05 | 2001-11-19 | 株式会社ビー・エム・エル | ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体 |
| US5962319A (en) | 1997-05-19 | 1999-10-05 | Bml, Inc. | Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene |
| JPH10155489A (ja) | 1996-11-27 | 1998-06-16 | Asahi Chem Ind Co Ltd | 組換え抗体及びそれをコードする核酸 |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| CN1307640A (zh) | 1998-05-25 | 2001-08-08 | 旭化成株式会社 | 细胞分离装置和分离方法 |
| US6090388A (en) | 1998-06-20 | 2000-07-18 | United Biomedical Inc. | Peptide composition for prevention and treatment of HIV infection and immune disorders |
| CA2299893A1 (en) | 1999-03-02 | 2000-09-02 | Carlos O. Stalgis | Hiv therapy |
| DE50211704D1 (de) | 2001-12-11 | 2008-03-27 | Biotectid Gmbh | Verwendung eines markierten liganden mit spezifität für das humane cd4-molekül |
| JP2003327536A (ja) | 2002-03-07 | 2003-11-19 | Kitasato Inst:The | ヒト免疫不全症候群ウイルスの感染、増殖抑制剤 |
| US20030211470A1 (en) | 2002-03-15 | 2003-11-13 | Olson William C. | CD4-IgG2-based salvage therapy of HIV-1 infection |
| US7501494B2 (en) | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| JP5020941B2 (ja) | 2005-05-02 | 2012-09-05 | マイメティクス コーポレーション | Ｈｉｖに対して中和活性を有するがｉｌ２には中和活性を有さない抗体又はその断片 |
| RU2393873C2 (ru) | 2005-05-02 | 2010-07-10 | Майметикс Корпорейшн | Антитело или его фрагмент, имеющие нейтрализующую активность в отношении вич, но не в отношении il2 |
| WO2007025276A2 (en) | 2005-08-25 | 2007-03-01 | Government Of The United States Of America, As Represented By The Secretary | Use of hiv envelope/ cd4 complexes as immunogenic complexes for the generation of antibodies |
| WO2007094983A2 (en) | 2006-02-03 | 2007-08-23 | Tanox, Inc. | Methods and compositions for the inhibition of hiv infection of t cells |
| EP2892561A1 (en) | 2012-09-07 | 2015-07-15 | Baylor Research Institute | Hiv vaccine compositions and methods |
| EP3839044A1 (en) | 2013-03-14 | 2021-06-23 | MacroGenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
| CA2913231A1 (en) * | 2013-05-24 | 2014-11-27 | Cooper Human Systems Llc | Methods and compositions for treatment of hiv infection |
| KR20170054478A (ko) * | 2014-09-16 | 2017-05-17 | 유나이티드 바이오메디칼 인크. | 경쟁적 ｈｉｖ 진입 억제를 매개하는 ｃｄ４에 대한 모노클로날 항체에 의한 hiv 감염의 치료 및 기능적 치유 |
| RU2019106804A (ru) * | 2016-08-13 | 2020-09-21 | Юнайтед Байофарма, Инк. | Лечение и устойчивая вирусологическая ремиссия при вич-инфекции у haart-стабилизированных пациентов с помощью антител против cd4 |
-
2017
- 2017-08-13 RU RU2019106804A patent/RU2019106804A/ru not_active Application Discontinuation
- 2017-08-13 SG SG10202100268RA patent/SG10202100268RA/en unknown
- 2017-08-13 SG SG11201901203PA patent/SG11201901203PA/en unknown
- 2017-08-13 CA CA3033728A patent/CA3033728A1/en active Pending
- 2017-08-13 CN CN201780050119.1A patent/CN109996815A/zh active Pending
- 2017-08-13 KR KR1020197007296A patent/KR20190071677A/ko not_active Ceased
- 2017-08-13 EP EP17841919.8A patent/EP3497133A4/en not_active Withdrawn
- 2017-08-13 US US16/325,361 patent/US11292839B2/en active Active
- 2017-08-13 BR BR112019002734-3A patent/BR112019002734A2/pt unknown
- 2017-08-13 MX MX2019001814A patent/MX2019001814A/es unknown
- 2017-08-13 AU AU2017312887A patent/AU2017312887A1/en not_active Abandoned
- 2017-08-13 WO PCT/US2017/046668 patent/WO2018035001A1/en not_active Ceased
- 2017-08-13 JP JP2019529466A patent/JP2019534891A/ja active Pending
- 2017-08-14 TW TW106127443A patent/TW201808998A/zh unknown
-
2019
- 2019-03-05 ZA ZA2019/01374A patent/ZA201901374B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3033728A1 (en) | 2018-02-22 |
| RU2019106804A3 (enExample) | 2021-03-29 |
| WO2018035001A1 (en) | 2018-02-22 |
| EP3497133A4 (en) | 2020-03-25 |
| KR20190071677A (ko) | 2019-06-24 |
| SG10202100268RA (en) | 2021-02-25 |
| AU2017312887A1 (en) | 2019-03-07 |
| US20190194326A1 (en) | 2019-06-27 |
| JP2019534891A (ja) | 2019-12-05 |
| RU2019106804A (ru) | 2020-09-21 |
| SG11201901203PA (en) | 2019-03-28 |
| US11292839B2 (en) | 2022-04-05 |
| TW201808998A (zh) | 2018-03-16 |
| EP3497133A1 (en) | 2019-06-19 |
| ZA201901374B (en) | 2022-04-28 |
| BR112019002734A2 (pt) | 2019-05-14 |
| CN109996815A (zh) | 2019-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001814A (es) | Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart. | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| MX392098B (es) | Anticuerpos neutralizantes de poliomavirus. | |
| EA201891186A1 (ru) | Антитела, нейтрализующие вирус иммунодефицита человека | |
| MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
| EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
| EP4406554A3 (en) | Anti-cd3 antibody formulations | |
| PH12015501648A1 (en) | 2-aminopyrimidine derivatives for the treatment of viral infections | |
| EP4327866A3 (en) | Mirikizumab in the treatment of ulcerative colitis | |
| PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| EA201690905A1 (ru) | Специфические антитела против cd38 для лечения злокачественных новообразований у человека | |
| JOP20190055A1 (ar) | أجسام مضادة ضد cd27 | |
| EA201792182A1 (ru) | Композиции и способы для лечения анемии | |
| AR100944A1 (es) | ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w | |
| MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
| TW201611845A (en) | Treatment and functional cure of HIV infection by monoclonal antibodies to CD4 mediating competitive HIV entry inhibition | |
| PH12015502564A1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
| MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
| PH12017500817A1 (en) | Long acting pharmaceutical compositions for hepatitis c | |
| PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
| MX2017002093A (es) | Terapia con anticuerpos para vih como sustituto de tratamiento. | |
| MX391162B (es) | Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5 | |
| MX2020006368A (es) | Uso de tratamiento combinado de anticuerpo pd-1 y apatinib para tratar cancer de mama triple negativo. | |
| EA202092573A1 (ru) | Композиции и способы обнаружения и лечения рака желудка |